ArticleSkin health and disease2023
The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review.
Article in Skin health and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2024Pooled it
- Topical anti-inflammatory treatments for eczema: network meta-analysis.The Cochrane database of systematic reviews · 2024Pooled it
- A phase II study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in patients with colorectal cancer receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).International journal of clinical oncology · 2025Trial
- Therapeutic Effect of Anti-inflammatory Tripeptide Cream in Hand-Foot Syndrome/Skin Reaction Related to Anticancer Drugs: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial.Cancer research and treatment · 2024Trial
- Integrative Approaches to Atopic Dermatitis: Exploring Biomarkers, Current Therapies, and the Potential Role of Osteopathic Manipulative Medicine.International journal of molecular sciences · 2026Review
- Clinical evidence on integrated Chinese-Western medicine for atopic dermatitis.Integrative medicine research · 2026Article
- Cumulative Life Course Impairment in Atopic Dermatitis: A Comprehensive Review.Medical sciences (Basel, Switzerland) · 2026Review
- GZ21T as an emerging topical dermatologic therapy: A literature review.Dermatology online journal · 2026Review
- Article
- Elucidating the Multi-Target Anti-Pruritic Mechanism ofCurrent issues in molecular biology · 2026Article
- Bioactive eggshell membrane-integrated nanofiber dressing with mesoporous polydopamine-mediated sustained dexamethasone delivery for enhanced wound regeneration.Journal of nanobiotechnology · 2026Article
- Exploring the Therapeutic Potential of Crisaborole Gel in Atopic Dermatitis: A Review.Recent advances in drug delivery and formulation · 2026Review
- From Bioactive Selenium Nanoparticles to Multifunctional Dermatological Platforms: Mechanism-Guided Design and Translational Challenges.International journal of nanomedicine · 2026Review
- Review
- Isosorbide Diesters: Mechanistic Insights and Therapeutic Applications in Skin and Neuroinflammatory Disorders.International journal of molecular sciences · 2025Review
- Recent advances in polymer-based drug delivery systems for atopic dermatitis: enhancing therapeutic efficacy and outcomes.Materials today. Bio · 2025Review
- Review
- Comparison of the Effectiveness Differences between Western and Chinese Medicinal Ointments against Eczema.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Chitosan Nanoparticles Loaded with Polyphenols for Cosmeceutical Applications: A State-of-the-Art Review.Pharmaceutics · 2025Review
- Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions.Inflammopharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Topical corticosteroids (TCS) are a first-line treatment for eczema, but there are concerns about their safety when used long-term. Objectives: To systematically review adverse effects associated with longer-term use of TCS for eczema. Methods: Randomised controlled trials (RCTs), cohort and case-control studies reporting adverse effects of TCS (comparators: no TCS treatment, other topicals) in patients with eczema were identified. Included studies had greater than one year of follow-up, minimum cohort size of 50 participants, or minimum 50 per arm for RCTs. Evidence was GRADE-assessed. Prospero registration CRD42021286413. Results: We found seven studies (two randomised, five observational); two RCTs ( Conclusion: This review provides some reassuring data on growth and skin thinning when TCS are used intermittently for up to 5 years, but many knowledge gaps remain.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.